Janssen Biotech takes aim at Humira

  • Janssen’s DTC ads for Tremfya take direct aim at Humira.
  • Ads show that Tremfya works better than Humira.
  • Website also shows Tremfya advantage.

Janssen’s new DTC ads have Humira in their crosshairs.  Not only do the TV ads clearly show that Tremfya works better than Humira, but the website has interactive graphics that directly attack the market leader.

Not only are they attacking Humira on results, they are also attacking with better patient assistance;

If you are starting TREMFYA®, your dermatologist’s office will check to see what your insurance covers. No matter what type of insurance you have, Janssen CarePath can help explain your medication insurance coverage and benefits.
If you are eligible, you may be able to lower your out-of-pocket costs for TREMFYA®. With the Janssen CarePath Savings Program for TREMFYA®, eligible patients with commercial or private insurance pay just $5 for each dose* for your TREMFYA® medication costs, with a $20,000 maximum program benefit each calendar year.

Clearly Janssen has done their homework.  They are giving patients a C:EAR reason to switch and removing barriers to treatment.  Congratulation to the marketing team!

Leave a Reply

Your email address will not be published. Required fields are marked *